{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:13:59Z","timestamp":1788902039827,"version":"build-2803163510"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    We report 4 patients with metastatic hormone-sensitive (mHSPC) or castration-resistant prostate cancer (mCRPC) treated with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 radioligand therapy (RLT), including rechallenge after disease progression. Initial RLT induced significant PSA declines, pain relief, and radiographic responses. Upon biochemical or clinical progression, rechallenge with additional\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA cycles achieved renewed PSA reductions, sustained symptomatic improvement, and favorable safety, with no grade III\u2013IV hematologic or renal toxicities. These cases illustrate the dynamic application of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA across disease stages and suggest that prior exposure does not preclude subsequent retreatment, supporting the feasibility and efficacy of RLT rechallenge in both mCRPC and mHSPC settings.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006490","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:05:42Z","timestamp":1785762342000},"page":"e901-e904","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Rechallenge With 177Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Faeze","family":"Rabani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoo","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Tanha Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.118.215715","article-title":"Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/RLU.0000000000005583","article-title":"Outcome and renal safety of PSMA-targeted radioligand therapy in mCRPC patients with preexisting impaired renal function","volume":"50","author":"Bastian","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/RLU.0000000000001480","article-title":"Excellent response to 177Lu-PSMA-617 radioligand therapy in a patient with advanced metastatic castration resistant prostate cancer evaluated by 68Ga-PSMA PET\/CT","volume":"42","author":"Roll","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","article-title":"Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer","volume":"43","author":"Kim","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/RLU.0000000000002655","article-title":"Complete regression of lung metastases in a patient with metastatic castration-resistant prostate cancer using 177Lu-PSMA radioligand therapy","volume":"45","author":"Zhang","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/RLU.0000000000005589","article-title":"Re-rechallenge 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"50","author":"Aggarwal","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/cancers15010297","article-title":"PSMA-RLT in patients with metastatic hormone-sensitive prostate cancer: a retrospective study","volume":"15","author":"Banda","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00508-025-02642-3","article-title":"[177Lu]Lu-PSMA radioligand therapy as an initial approach in hormone-sensitive metastatic prostate cancer: a case report","volume":"138","author":"Langrate","year":"2026","journal-title":"Wien Klin Wochenschr"},{"key":"R13-20260908","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00259-024-06825-4","article-title":"Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)","volume":"51","author":"Rosar","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00259-025-07438-1","article-title":"Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"53","author":"Belabaci","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20260908","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00259-024-06905-5","article-title":"Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer","volume":"52","author":"Santo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20260908","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.123.267321","article-title":"Safety and efficacy of extended therapy with [ 177 Lu]Lu-PSMA: a German multicenter study","volume":"65","author":"Seifert","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:00:45Z","timestamp":1788901245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006490"}},"subtitle":["Lessons From a Multicase Experience"],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006490","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"2026-01-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}